Hyeon-Mi Yoo

Title: Hyeon-Mi Yoo: Innovator in Monoclonal Antibody Research

Introduction

Hyeon-Mi Yoo is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies. With a total of 3 patents to his name, Yoo's work is paving the way for advancements in cancer treatment.

Latest Patents

One of Hyeon-Mi Yoo's latest patents is focused on a human monoclonal antibody that neutralizes vascular endothelial growth factor receptor. This invention relates to human ScFv molecules that inhibit angiogenesis and provide a composition for treating cancer. The disclosed monoclonal antibody demonstrates excellent neutralizing ability in living cells, outperforming commercially available antibodies against vascular endothelial growth factor receptor. It has shown effectiveness in neutralizing the receptor not only in humans but also in mice and rats. This innovation holds promise for anticancer studies and is expected to be highly effective in cancer treatment.

Career Highlights

Hyeon-Mi Yoo is currently associated with Pharmabcine Inc., where he continues to advance his research in monoclonal antibodies. His work is instrumental in developing therapies that could significantly impact cancer treatment.

Collaborations

Yoo collaborates with notable colleagues, including Jin-San Yoo and Weon-Sup Lee, contributing to a dynamic research environment that fosters innovation.

Conclusion

Hyeon-Mi Yoo's contributions to the field of monoclonal antibodies are noteworthy and have the potential to revolutionize cancer treatment. His ongoing research and collaborations are expected to yield significant advancements in medical science.